DP
KOSDAQ: 347850
D&D Pharmatech is a South Korea-based biotechnology developer focusing on investigational medicines for metabolic and other serious diseases. Its official site describes GLP-1 peptide-based treatments and oral peptide technologies alongside global clinical development efforts. The Korean Financial Supervisory Service company record identifies the issuer as D&D Pharmatech Inc., KOSDAQ code 347850, with an office in Seongnam. This directory records the listed parent and platform-level focus without attempting to maintain every clinical asset or licensing territory. The company’s official pipeline and investor materials provide up-to-date development information.
South Korea
peptide-therapeutics · GLP-1 · drug-discovery
metabolic-disease · MASH · obesity
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →DS
TSE: 4568
Daiichi Sankyo is a Japanese global pharmaceutical company researching, developing and commercializing prescription medicines. Its R&D activities include small molecules, biologic approaches and antibody-drug conjugate technologies, with significant work in oncology and selected cardiovascular and specialty diseases. The company maintains research and commercial operations internationally and collaborates with other drug developers. Headquartered in Tokyo, Daiichi Sankyo is listed on the Tokyo Stock Exchange under securities code 4568. This profile is intended as a stable directory description, not as an exhaustive catalog of products, treatment indications or clinical phases.
Japan
antibody-drug conjugates · small molecules · biologics
oncology · cardiovascular diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →DTEuronext Paris: DBV Nasdaq: DBVT
DBV Technologies is a France-based biopharmaceutical company developing epicutaneous immunotherapies for allergic conditions. Its technology is designed to deliver allergens through the skin to help modulate immune responses, with development efforts focused on food allergies and related diseases. DBV has research and clinical development activities aimed at evaluating this approach in patients with significant unmet needs. The company's ordinary shares trade on Euronext Paris under DBV, while American depositary shares trade on Nasdaq under DBVT. These are different securities linked to one issuer, not separate company records.
France
epicutaneous immunotherapy · allergen delivery
food allergy · immunology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →DT
Nasdaq: DYN
Dyne Therapeutics is a U.S. clinical-stage biotechnology company developing medicines for genetically driven neuromuscular disorders. The company's scientific approach focuses on delivering therapeutic molecules to muscle and related tissues, including oligonucleotide technologies designed to modify disease-associated processes. It works on rare inherited conditions for which delivery to affected tissue is an important challenge in drug development. Based in Waltham, Massachusetts, Dyne is listed on Nasdaq under DYN. Its therapeutic research spans candidate design, delivery-system optimization and clinical evaluation in defined neuromuscular patient populations. Dyne's development strategy is centered on disease biology and the potential benefits of targeted drug delivery.
United States
targeted oligonucleotide delivery · conjugated medicines
neuromuscular disorders · rare genetic diseases
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →EM
HKEX: 01952
Everest Medicines is a Hong Kong-listed biopharmaceutical company engaged in developing, manufacturing and commercializing innovative medicines. The company works with internally developed capabilities and external partnerships to bring therapies to patients, with activities spanning several disease areas. Its portfolio and development strategy have included immunology, infectious diseases, renal conditions and other therapeutic needs. The official company website identifies its Hong Kong listing and provides investor disclosures alongside business information. Its work connects therapeutic development with manufacturing capabilities and commercial partnerships.
China
mRNA therapeutics · drug development and commercialization
autoimmune disease · ophthalmology · cardiovascular and kidney disease · oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →G&SSE: 603087
Gan & Lee Pharmaceuticals is a listed Chinese pharmaceutical company specializing in medicines for diabetes and other metabolic diseases. It has extensive experience developing and manufacturing insulin products, including insulin analogues, and has expanded research into additional therapeutic areas. Its official corporate website displays the Shanghai stock code and describes its research, manufacturing and international business. The company's activities include both commercial pharmaceutical operations and continued drug development. Its research and manufacturing are anchored in therapies for diabetes and metabolic disorders.
China
insulin analogs · peptide therapeutics
diabetes · obesity · metabolic disease
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →GANasdaq Copenhagen: GMAB Nasdaq: GMAB
Genmab is a Denmark-based biotechnology company developing innovative antibody therapeutics through proprietary antibody-science platforms and collaborations. Its research emphasizes treatments for cancer and other serious diseases and extends from therapeutic discovery into clinical development and commercialization. Its official company pages describe multiple proprietary technologies, while its annual report documents the issuer across Nasdaq Copenhagen and the Nasdaq US market under GMAB. The directory treats the dual listings as one corporate entity.
Denmark
therapeutic-antibodies · bispecific-antibodies · antibody-platforms
oncology · serious-diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →GPLSE: GSK NYSE: GSK
GSK is a United Kingdom-based biopharmaceutical company that researches, develops, manufactures and commercializes specialty medicines and vaccines. Its therapeutic focus includes infectious diseases, immunology and oncology, using vaccine science and a range of medicinal approaches. The official investor website confirms London-listed ordinary shares and New York-listed American depositary shares under the GSK symbol; these are representations of one listed company. Its development work integrates vaccines, specialty medicines and research into immune-mediated diseases.
United Kingdom
vaccines · small-molecule · biologics
infectious-diseases · immunology · oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →HP
HKEX: 03692
Hansoh Pharmaceutical Group is a listed pharmaceutical company based in China with substantial research, development and commercialization activities. The company develops innovative small-molecule and biological medicines and also operates a broader pharmaceutical business. Its official website describes oncology, central nervous system disorders, metabolic conditions, infections and immunology among its therapeutic areas. The corporate site identifies its Hong Kong stock code and offers links to its ongoing research and investor information. This entry focuses on the listed issuer and its enduring drug-development capabilities, rather than reproducing a rapidly changing inventory of products, research assets or financial results.
China
small-molecule pharmaceuticals · biologics
oncology · metabolic disease · immunology · central nervous system · infectious disease
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →HHHKEX: 02142
Harbour BioMed, also known through its listed entity HBM Holdings, is a Hong Kong-listed biopharmaceutical company developing antibody-based therapeutics. Its technology platforms include the discovery of fully human antibodies, heavy-chain-only antibodies and additional engineered antibody formats. Oncology and immunology are important therapeutic areas. The company combines proprietary discovery activities with research partnerships and licensing arrangements. Its official website describes its antibody platform and identifies the Hong Kong listing. These antibody engineering capabilities support its oncology and immunology research strategy.
China
fully human antibodies · heavy-chain-only antibodies · bispecific immune-cell engagers
oncology · immunology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →HTNasdaq Global Select Market: COAG
Hemab Therapeutics is a biotechnology company developing investigational medicines for inherited and other serious disorders of blood coagulation. Its therapeutic research focuses on treatments intended to address conditions associated with abnormal bleeding and clot formation. The company conducts development activities spanning biological medicines and clinical research, with operations in the United States and Denmark. Hemab operates as a publicly listed issuer and makes corporate disclosures available through its investor relations website.
United States
antibody therapeutics · hematology
coagulation disorders · rare diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →HP
SSE STAR: 688302
Hinova Pharmaceuticals is a China-based company involved in innovative medicine discovery, development and commercialization. Its research interests include oncology, metabolic disorders, autoimmune diseases and chronic inflammatory conditions. The company pursues small-molecule therapeutic approaches and differentiated drug-development strategies. Its official website identifies its Shanghai STAR Market securities code as 688302. Hinova's pharmaceutical activities encompass research into disease biology, candidate selection and clinical development, alongside industrialization planning for drug products. Its therapeutic focus differentiates the company from manufacturers solely producing established generic medicines or organizations limited to contract research services. The company operates within China's publicly listed innovative-drug development sector.
China
targeted protein degradation · PROTAC · deuterated medicines
oncology · metabolic disease · autoimmune disease
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →IHNasdaq: IMCR
Immunocore Holdings is a United Kingdom-headquartered biotechnology company developing and commercializing T-cell receptor-based immunotherapies. Its platform uses engineered soluble T-cell receptors to engage immune mechanisms against targeted diseased cells. The company's therapeutic work includes oncology and investigational approaches for autoimmune and infectious diseases. Immunocore's shares trade on Nasdaq under IMCR, while the company's operational headquarters are in Oxfordshire, England. This concise profile records its technology and disease-area orientation rather than continually tracking the stages of individual programs.
United Kingdom
T-cell receptor therapeutics · soluble bispecific immunotherapies
oncology · autoimmune disease · infectious disease
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →IBHKEX: 01801
Innovent Biologics is a China-based biopharmaceutical company involved in research, development, manufacturing and commercialization of innovative medicines. Its technology base includes therapeutic antibodies and other protein-based medicines, with research across cancer, autoimmune diseases and cardiometabolic disorders. The company works with internal scientific teams and external partners to develop therapies and expand access to treatment. Innovent maintains an official corporate website and investor communications for its Hong Kong-listed issuer. Its principal approach brings biologic discovery together with clinical and commercial development.
China
antibodies · protein therapeutics
oncology · autoimmune disease · cardiovascular and metabolic disease · ophthalmology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →IT
Nasdaq: NTLA
Intellia Therapeutics is a U.S. biotechnology company developing medicines based on genome editing, including CRISPR-based technologies. Its research aims to create genetic interventions for serious diseases, with drug development programs evaluating targeted editing in relevant tissues. The company's therapeutic interests include rare inherited and protein-mediated conditions. Intellia is headquartered in Cambridge, Massachusetts, and its common stock trades on Nasdaq under NTLA. It operates as a research-driven therapeutic developer rather than a contract-service or diagnostic-only company. This entry summarizes enduring modality and disease-area characteristics without claiming that investigational therapies are approved.
United States
CRISPR gene editing · genome engineering
rare genetic diseases · hereditary angioedema · cardiomyopathy
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →IP
Nasdaq: IONS
Ionis Pharmaceuticals is a United States company focused on medicines that target RNA to address serious diseases. Its research and marketed medicines draw on oligonucleotide technologies, including antisense approaches that can change production or processing of disease related proteins. Its therapeutic areas include neurological and cardiometabolic conditions, alongside selected rare diseases. Founded in 1989, Ionis is headquartered in Carlsbad, California, and has conducted public trading under the Nasdaq ticker IONS. Several medicines are developed independently and through partnerships.
United States
antisense oligonucleotides · RNA-targeted medicines
neurology · cardiometabolic · rare diseases
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →JPTSE Prime: 4552
JCR Pharmaceuticals is a Japan-based research-oriented biopharmaceutical company specializing in therapies for rare and genetic diseases. Its scientific work includes biologics and a proprietary blood-brain-barrier delivery technology for central nervous system applications. The company is also involved in regenerative and other advanced medicinal approaches. Its official Japanese and English corporate information confirms headquarters in Ashiya, Hyogo, and a Tokyo Stock Exchange Prime Market listing under 4552. These capabilities support programs focused on rare genetic conditions and central nervous system delivery.
Japan
biologics · blood-brain-barrier-delivery · cell-therapy
rare-diseases · neurology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →JYSSE STAR: 688176
Jiangsu Yahong Meditech, also known as Asieris Pharmaceuticals, is a Chinese biotechnology company developing therapeutics for oncology and related urologic conditions. Its work includes discovery, clinical development and commercialization-oriented research for serious diseases, with particular experience in drug candidates designed for specialized patient populations. The company is listed on the Shanghai Stock Exchange STAR Market under code 688176 and maintains corporate operations in China. This directory treats it as an innovative drug developer rather than a contract-service provider, while keeping its changing individual development programs outside the permanent profile.
China
small molecules · oncology drug development
oncology · urologic diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →KBHKEX: 02162
Keymed Biosciences is a Hong Kong-listed biopharmaceutical company focused on discovering and developing novel therapeutic antibodies. Its research includes antibodies, multispecific formats and antibody-drug conjugates, with a focus on immune-mediated diseases, chronic conditions and cancers. The company has capabilities extending from early discovery through clinical development and works toward manufacturing and commercialization of selected treatments. Its website provides corporate information and descriptions of key technology platforms. Antibody engineering and immune disease research remain central to its scientific positioning.
China
antibody therapeutics · bispecific antibodies · antibody-drug conjugates
autoimmune disease · oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →KP
HKEX: 09939
Kintor Pharmaceutical is a Chinese drug-development company working on targeted treatments for dermatological and other diseases. Its therapeutic research has included androgen-receptor-directed compounds, topical treatments for androgenetic alopecia, and experimental approaches aimed at oncology targets. Kintor is publicly listed in Hong Kong under stock code 9939. While the group also describes work involving dermatology-related cosmetic ingredients, that activity is distinct from its investigational therapeutic drug programs. The company maintains research and development operations in Suzhou and provides updates through its corporate website and stock-exchange disclosures.
China
androgen receptor modulation · targeted small molecules · protein degradation
dermatology · oncology
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →KKTSE: 4151
Kyowa Kirin is a Japanese global specialty pharmaceutical company developing and commercializing medicines for serious and often underserved conditions. Its research capabilities include antibody-based medicines and other biologic or targeted therapeutic approaches supported by clinical development and specialized manufacturing. The company has long worked in rare diseases and selected hematology and immunology markets. Based in Japan, Kyowa Kirin is listed on the Tokyo Stock Exchange under security code 4151. This directory records its stable therapeutic activities and technology orientation, without attempting to track every product indication or licensing agreement.
Japan
antibody medicines · specialty biologics
rare diseases · hematology · immunology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →LB
Nasdaq: LEGN
Legend Biotech is a publicly traded biotechnology company focused on developing and commercializing engineered cell therapies, particularly chimeric antigen receptor T-cell approaches. Its drug development combines cell engineering, translational science, clinical studies and commercial collaborations. The company has a major United States operating presence and a global headquarters in Bridgewater, New Jersey, while its listed issuer has a separate corporate legal structure. Legend trades on Nasdaq under LEGN. Its work centers on cancer therapies, including hematologic malignancies, with additional research into next-generation cell approaches.
United States
CAR-T · engineered cell therapy
hematologic oncology · cancer
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →M(SSE STAR: 688062 HKEX: 02493
Mabwell is a China-based innovative biopharmaceutical company involved in discovering, developing, manufacturing and commercializing biologic medicines. Its scientific platforms include antibody discovery and engineering, as well as antibody-drug conjugate technologies. Research areas include oncology and immune-related disease. The company's official website identifies its Shanghai and Hong Kong stock codes and describes its integrated research and production capabilities. Both stock listings belong under the same issuer identity. The company integrates antibody platform research with pharmaceutical process and manufacturing capabilities.
China
antibody engineering · antibody-drug conjugates
oncology · immunology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →MI
Nasdaq: MRNA
Moderna is a U.S. biotechnology company developing medicines using messenger RNA technology and related delivery and manufacturing capabilities. Its platform supports the design and production of RNA-based therapeutics and vaccines, with research extending beyond infectious disease into oncology and selected other conditions. Moderna is headquartered in Cambridge, Massachusetts, and its common shares are listed on Nasdaq under MRNA. The company's scientific strategy combines sequence design, drug delivery, clinical development and commercial-scale production.
United States
mRNA therapeutics · lipid nanoparticles
infectious diseases · oncology · rare diseases
Verified: 2026-11-08T23:28:35.680Z
Profile and official sources → 